Skip to main content

Articles

Page 32 of 39

  1. We previously reported a PI3K inhibitor S14161 which displays a promising preclinical activity against multiple myeloma (MM) and leukemia, but the chiral structure and poor solubility prevent its further appli...

    Authors: Kunkun Han, Xin Xu, Guodong Chen, Yuanying Zeng, Jingyu Zhu, Xiaolin Du, Zubin Zhang, Biyin Cao, Zhaopeng Liu and Xinliang Mao
    Citation: Journal of Hematology & Oncology 2014 7:9
    Content type: Research Published on:

  2. Oncologic patients who are extreme responders to molecularly targeted therapy provide an important opportunity to better understand the biologic basis of response and, in turn, inform clinical decision making....

    Authors: Vivek Subbiah, Shannon N Westin, Kai Wang, Dejka Araujo, Wei-Lien Wang, Vincent A Miller, Jeffrey S Ross, Phillip J Stephens, Gary A Palmer and Siraj M Ali
    Citation: Journal of Hematology & Oncology 2014 7:8
    Content type: Short report Published on:

  3. Despite encouraging results with the proteasome inhibitor bortezomib in the treatment of hematologic malignancies, emergence of resistance can limit its efficacy, hence calling for novel strategies to overcome...

    Authors: Denise Niewerth, Gertjan JL Kaspers, Yehuda G Assaraf, Johan van Meerloo, Christopher J Kirk, Janet Anderl, Jonathan L Blank, Peter M van de Ven, Sonja Zweegman, Gerrit Jansen and Jacqueline Cloos
    Citation: Journal of Hematology & Oncology 2014 7:7
    Content type: Research Published on:

  4. The purpose of this study was to detect the serum microRNAs (miRNAs) that are differentially expressed in cervical squamous cell carcinoma (SCC) patients and negative controls, with a focus on the miRNA profil...

    Authors: Wen-Tao Wang, Ya-Nan Zhao, Jin-Xing Yan, Mei-Ying Weng, Yan Wang, Yue-Qin Chen and Shun-Jia Hong
    Citation: Journal of Hematology & Oncology 2014 7:6
    Content type: Rapid communication Published on:

  5. The majority of patients with acute myelogenous leukemia (AML) still die of their disease. In order to improve survival rates in AML patients, new strategies are necessary to discover biomarkers for the detect...

    Authors: Mingli Yang, Guohua Jiang, Wenjing Li, Kai Qiu, Min Zhang, Christopher M Carter, Samer Z Al-Quran and Ying Li
    Citation: Journal of Hematology & Oncology 2014 7:5
    Content type: Research Published on:

  6. Wilms tumor 1 (WT1) is over-expressed in numerous cancers with respect to normal cells, and has either a tumor suppressor or oncogenic role depending on cellular context. This gene is associated with numerous ...

    Authors: Amy Guillaumet-Adkins, Julia Richter, Maria D Odero, Juan Sandoval, Xabi Agirre, Albert Catala, Manel Esteller, Felipe Prósper, María José Calasanz, Ismael Buño, Mi Kwon, Franck Court, Reiner Siebert and David Monk
    Citation: Journal of Hematology & Oncology 2014 7:4
    Content type: Research Published on:

  7. Because WT1 is expressed in leukemia cells, the development of cancer immunotherapy targeting WT1 has been an attractive translational research topic. However, concern of this therapy still remains, since WT1 ...

    Authors: Hiroaki Asai, Hiroshi Fujiwara, Sohei Kitazawa, Naoto Kobayashi, Toshiki Ochi, Yukihiro Miyazaki, Fumihiro Ochi, Yoshiki Akatsuka, Sachiko Okamoto, Junichi Mineno, Kiyotaka Kuzushima, Hiroaki Ikeda, Hiroshi Shiku and Masaki Yasukawa
    Citation: Journal of Hematology & Oncology 2014 7:3
    Content type: Letter to the Editor Published on:

  9. Inhibition of AKT with MK-2206 has demonstrated synergism with anticancer agents. This phase 1 study assessed the MTD, DLTs, PK, and efficacy of MK-2206 in combination with cytotoxic and targeted therapies.

    Authors: L Rhoda Molife, Li Yan, Joanna Vitfell-Rasmussen, Adriane M Zernhelt, Daniel M Sullivan, Philippe A Cassier, Eric Chen, Andrea Biondo, Ernestina Tetteh, Lillian L Siu, Amita Patnaik, Kyriakos P Papadopoulos, Johann S de Bono, Anthony W Tolcher and Susan Minton
    Citation: Journal of Hematology & Oncology 2014 7:1
    Content type: Research Published on:

  11. The dismal outcome of malignant peripheral nerve sheath tumor (MPNST) highlights the necessity of finding new therapeutic methods to benefit patients with this aggressive sarcoma. Our purpose was to investigat...

    Authors: Xiaoling Du, Jilong Yang, Antti Ylipää and Ze Zhu
    Citation: Journal of Hematology & Oncology 2013 6:93
    Content type: Research Published on:

  12. MET is a receptor tyrosine kinase that is activated by the ligand HGF and this pathway promotes cell survival, migration, and motility. In accordance with its oncogenic role, MET is constitutively active, muta...

    Authors: Cornel Joseph Phillip, Shadia Zaman, Shujun Shentu, Kumudha Balakrishnan, Jiexin Zhang, Veera Baladandayuthapani, Pietro Taverna, Sanjeev Redkar, Michael Wang, Christine Marie Stellrecht and Varsha Gandhi
    Citation: Journal of Hematology & Oncology 2013 6:92
    Content type: Research Published on:

  14. Signal Transducer and Activator of Transcription (STAT) proteins are a family of cytoplasmic transcription factors consisting of 7 members, STAT1 to STAT6, including STAT5a and STAT5b. STAT proteins are though...

    Authors: Muhammad Furqan, Akintunde Akinleye, Nikhil Mukhi, Varun Mittal, Yamei Chen and Delong Liu
    Citation: Journal of Hematology & Oncology 2013 6:90
    Content type: Review Published on:

  15. The chemokine receptor CCR7 mediates lymphoid dissemination of many cancers, including lymphomas and epithelial carcinomas, thus representing an attractive therapeutic target. Previous results have highlighted...

    Authors: Beatriz Somovilla-Crespo, Manuel Alfonso-Pérez, Carlos Cuesta-Mateos, Cristina Carballo-de Dios, Amada E Beltrán, Fernando Terrón, Juan J Pérez-Villar, Carlos Gamallo-Amat, Gema Pérez-Chacón, Elena Fernández-Ruiz, Juan M Zapata and Cecilia Muñoz-Calleja
    Citation: Journal of Hematology & Oncology 2013 6:89
    Content type: Research Published on:

  16. Phosphatidylinositol 3-kinases (PI3Ks) are lipid kinases that regulate diverse cellular processes including proliferation, adhesion, survival, and motility. Dysregulated PI3K pathway signaling occurs in one-th...

    Authors: Akintunde Akinleye, Parthu Avvaru, Muhammad Furqan, Yongping Song and Delong Liu
    Citation: Journal of Hematology & Oncology 2013 6:88
    Content type: Review Published on:

  17. Recent findings have shown that the blood vessels of different organs exert an active role in regulating organ function. In detail, the endothelium that aligns the vasculature of most organs is fundamental in ...

    Authors: Ana Costa, Joana Afonso, Catarina Osório, Ana L Gomes, Francisco Caiado, Joana Valente, Sandra I Aguiar, Francisco Pinto, Mário Ramirez and Sérgio Dias
    Citation: Journal of Hematology & Oncology 2013 6:87
    Content type: Short report Published on:

  18. The gastrointestinal (GI) tract is one of the most common extranasal sites in extranodal NK/T-cell lymphoma (ENKTL). However, data regarding ENKTL involving the GI tract are relatively scarce. Thus, we perform...

    Authors: Seok Jin Kim, Hyun Ae Jung, Shih-Sung Chuang, Huangming Hong, Cheng-Cheng Guo, Junning Cao, Xiao-Nan Hong, Ritsuro Suzuki, Hye Jin Kang, Jong Ho Won, Wee-Joo Chng, Yok-Lam Kwong, Cheolwon Suh, Yu-Qin Song, Jun Zhu, Kevin Tay…
    Citation: Journal of Hematology & Oncology 2013 6:86
    Content type: Research Published on:

  19. In acute myeloid leukemia (AML), the leukemia initiating cells (LICs) or leukemia stem cells (LSCs) is found within the CD34+CD38- cell compartment. The LICs subpopulation survives chemotherapy and is most probab...

    Authors: Libing Wang, Lei Gao, Sheng Xu, Shenglan Gong, Li Chen, Shuqing Lü, Jie Chen, Huiying Qiu, Xiaoqian Xu, Xiong Ni, Xianmin Song, Weiping Zhang, Jianmin Yang, Min Liu, Xiaoxia Hu and Jianmin Wang
    Citation: Journal of Hematology & Oncology 2013 6:85
    Content type: Short report Published on:

  20. Hematopoietic stem cells (HSCs) are widely used in transplantation therapy to treat a variety of blood diseases. The success of hematopoietic recovery is of high importance and closely related to the patient’s...

    Authors: Wenbin Liao, Jerell R Aguila, Yixin Yao, Jianchang Yang, Gary Zieve, Yongping Jiang, Cecilia Avila, Lisa Senzel, Raymond Lai, Dazhong Xu, Wei Dai and Yupo Ma
    Citation: Journal of Hematology & Oncology 2013 6:84
    Content type: Research Published on:

  21. TP53 defects, i.e. 17p13 deletion and/or nucleotide mutations, associate with short survival and chemorefractoriness in chronic lymphocytic leukemia (CLL). In this context, since direct sequencing of the TP53 gen...

    Authors: Federico Pozzo, Michele Dal Bo, Nadia Peragine, Riccardo Bomben, Antonella Zucchetto, Francesca Maria Rossi, Massimo Degan, Davide Rossi, Annalisa Chiarenza, Alberto Grossi, Francesco Di Raimondo, Francesco Zaja, Gabriele Pozzato, Paola Secchiero, Gianluca Gaidano, Giovanni Del Poeta…
    Citation: Journal of Hematology & Oncology 2013 6:83
    Content type: Research Published on:

  22. T-cell large granular lymphocytic leukemia (T-LGLL) is a rare lymphoproliferative disorder and can cooccur in the context of pure red cell aplasia (PRCA). The aim of the current study was to analyze the signal...

    Authors: Zhi-Yuan Qiu, Lei Fan, Li Wang, Chun Qiao, Yu-Jie Wu, Jian-Feng Zhou, Wei Xu and Jian-Yong Li
    Citation: Journal of Hematology & Oncology 2013 6:82
    Content type: Letter to the Editor Published on:

  23. Ruxolitinib, a Janus kinase 1 and 2 inhibitor, demonstrated improvements in spleen volume, symptoms, and survival over placebo and best available therapy in intermediate-2 or high-risk myelofibrosis patients w...

    Authors: Moshe Talpaz, Ronald Paquette, Lawrence Afrin, Solomon I Hamburg, Josef T Prchal, Katarzyna Jamieson, Howard R Terebelo, Gregory L Ortega, Roger M Lyons, Ramon V Tiu, Elliott F Winton, Kavita Natrajan, Olatoyosi Odenike, David Claxton, Wei Peng, Peter O’Neill…
    Citation: Journal of Hematology & Oncology 2013 6:81
    Content type: Research Published on:

  24. Zoledronic acid is a potent inhibitor of osteoclast-mediated bone resorption and has been widely used in bone metastasis malignancies and postmenopausal osteoporosis as a preventive therapy against skeletal-re...

    Authors: Mingfeng He, Weidong Fan and Xianquan Zhang
    Citation: Journal of Hematology & Oncology 2013 6:80
    Content type: Research Published on:

  26. The involvement of protein kinase CK2 in sustaining cancer cell survival could have implications also in the resistance to conventional and unconventional therapies. Moreover, CK2 role in blood tumors is rapid...

    Authors: Laura Quotti Tubi, Carmela Gurrieri, Alessandra Brancalion, Laura Bonaldi, Roberta Bertorelle, Sabrina Manni, Laura Pavan, Federica Lessi, Renato Zambello, Livio Trentin, Fausto Adami, Maria Ruzzene, Lorenzo A Pinna, Gianpietro Semenzato and Francesco Piazza
    Citation: Journal of Hematology & Oncology 2013 6:78
    Content type: Research Published on:

  27. The role of IGF binding protein 2 (IGFBP2) in cancer development is intriguing. Previously we identified IGFBP2 as an extrinsic factor that supports the activity of hematopoietic stem cells (HSCs).

    Authors: Xiaoli Chen, Junke Zheng, Yizhou Zou, Chun Song, Xuemei Hu and Cheng Cheng Zhang
    Citation: Journal of Hematology & Oncology 2013 6:72
    Content type: Research Published on:

  28. Epidermal growth factor receptor- tyrosine kinase inhibitors (EGFR-TKIs) benefit Non-small cell lung cancer (NSCLC) patients, and an EGFR-TKIi erlotinib, is approved for patients with recurrent NSCLC. However,...

    Authors: Aamir Ahmad, Ma’in Y Maitah, Kevin R Ginnebaugh, Yiwei Li, Bin Bao, Shirish M Gadgeel and Fazlul H Sarkar
    Citation: Journal of Hematology & Oncology 2013 6:77
    Content type: Research Published on:

  29. Although knowledge of the genetics of diffuse large B-cell lymphoma (DLBCL) has been increasing, little is known about the characteristics and prognostic significance of cytogenetic abnormalities and the clini...

    Authors: Seon Young Kim, Hyo Jung Kim, Hye Jin Kang, Jin Seok Kim, Hyeon Seok Eom, Tae Min Kim, Sung-Soo Yoon, Cheolwon Suh and Dong Soon Lee
    Citation: Journal of Hematology & Oncology 2013 6:76
    Content type: Research Published on:

  30. Administration of recombinant G-CSF following cytoreductive therapy enhances the recovery of myeloid cells, minimizing the risk of opportunistic infection. Free G-CSF, however, is expensive, exhibits a short h...

    Authors: Mark P Rubinstein, Mohamed L Salem, Andrew L Doedens, Caitlin J Moore, Cody Chiuzan, Guillermo L Rivell, David J Cole and Ananda W Goldrath
    Citation: Journal of Hematology & Oncology 2013 6:75
    Content type: Research Published on:

  31. T-cell activation and dysfunction relies on direct and modulated receptors. Based on their functional outcome, co-signaling molecules can be divided as co-stimulators and co-inhibitors, which positively and ne...

    Authors: Li Shi, Shaohua Chen, Lijian Yang and Yangqiu Li
    Citation: Journal of Hematology & Oncology 2013 6:74
    Content type: Review Published on:

  32. Myelodysplastic syndromes (MDS) are a group of heterogeneous diseases with variable clinical course. Predicting disease progression is difficult due to lack of specific molecular marker(s). SALL4 plays importa...

    Authors: Fei Wang, Ye Guo, Qian Chen, Zhuo Yang, Ning Ning, Yujuan Zhang, Yonggang Xu, Xiaodong Xu, Chunrong Tong, Li Chai and Wei Cui
    Citation: Journal of Hematology & Oncology 2013 6:73
    Content type: Research Published on:

  33. Given potential values of induced pluripotent stem (iPS) cells in basic biomedical research and regenerative medicine, it is important to understand how these cells regulate their genome stability in response ...

    Authors: Yinghua Lu, Dazhong Xu, Jing Zhou, Yupo Ma, Yongping Jiang, Wenxian Zeng and Wei Dai
    Citation: Journal of Hematology & Oncology 2013 6:71
    Content type: Research Published on:

  34. The advent of tyrosine kinase inhibitors has produced 5-year survival of 90 + % for chronic myelocytic leukemia (CML) patients in clinical trials. However, population level survival has been lower, especially ...

    Authors: Dianne Pulte, Benjamin Barnes, Lina Jansen, Nora Eisemann, Katharina Emrich, Adam Gondos, Stefan Hentschel, Bernd Holleczek, Klaus Kraywinkel and Hermann Brenner
    Citation: Journal of Hematology & Oncology 2013 6:70
    Content type: Research Published on:

  35. Peripheral T/NK-cell lymphomas (PTCL) are rare malignancies with a poor prognosis. Due to the lack of randomised studies, standard therapy has not been established. First-line treatment with anthracycline-base...

    Authors: Peter Reimer and Shanta Chawla
    Citation: Journal of Hematology & Oncology 2013 6:69
    Content type: Case report Published on:

  36. We have characterized the molecular changes underlying the transformation of a JAK2V617F+-myelofibrosis with trisomy 8, into a JAK2V617F-negative leukemia. Leukemic clone did not carry JAK2V617F mutation, but sho...

    Authors: Francisca Ferrer-Marín, Beatriz Bellosillo, Luz Martínez-Avilés, Gloria Soler, Pablo Carbonell, Ginés Luengo-Gil, Eva Caparrós, José M Torregrosa, Carlos Besses and Vicente Vicente
    Citation: Journal of Hematology & Oncology 2013 6:68
    Content type: Letter to the Editor Published on:

  37. Pancreatic Ductal Adenocarcinoma (PDAC) is a highly aggressive malignancy with only a 5% 5-year survival rate. Reliable biomarkers for early detection are still lacking. The goals of this study were (a) to ide...

    Authors: Michela Capello, Paola Cappello, Federica Caterina Linty, Roberto Chiarle, Isabella Sperduti, Anna Novarino, Paola Salacone, Giorgia Mandili, Alessio Naccarati, Carlotta Sacerdote, Stefania Beghelli, Samantha Bersani, Stefano Barbi, Claudio Bassi, Aldo Scarpa, Paola Nisticò…
    Citation: Journal of Hematology & Oncology 2013 6:67
    Content type: Research Published on:

  38. Gastroesophageal cancer (GEC) remains a challenging problem in oncology. Anatomically, GEC is comprised of distal gastric adenocarcinoma (GC), classically associated with Helicobacter Pylori, while proximal esoph...

    Authors: Amikar Sehdev and Daniel VT Catenacci
    Citation: Journal of Hematology & Oncology 2013 6:66
    Content type: Review Published on:

  39. Erythropoietin (EPO) provides an alternative to transfusion for increasing red blood cell mass and treating anemia in cancer patients. However, recent studies have reported increased adverse events and/or redu...

    Authors: Makito Miyake, Steve Goodison, Adrienne Lawton, Ge Zhang, Evan Gomes-Giacoia and Charles J Rosser
    Citation: Journal of Hematology & Oncology 2013 6:65
    Content type: Research Published on:

  40. Despite the success of imatinib and other tyrosine kinase inhibitors (TKIs), chronic myeloid leukemia (CML) remains largely incurable, and a number of CML patients die due to Abl mutation-related drug resistance ...

    Authors: Qi Shen, Sichu Liu, Yu Chen, Lijian Yang, Shaohua Chen, Xiuli Wu, Bo Li, Yuhong Lu, Kanger Zhu and Yangqiu Li
    Citation: Journal of Hematology & Oncology 2013 6:64
    Content type: Research Published on:

  41. The natural history of inhibitors in patients with haemophilia A not undergoing immune tolerance induction (ITI) is largely unknown. A recent randomized controlled trial suggests that the higher the FVIII dose...

    Authors: Giuseppe Tagariello, Alfonso Iorio, Davide Matino, Donata Belvini, Roberta Salviato, Roberto Sartori and Paolo Radossi
    Citation: Journal of Hematology & Oncology 2013 6:63
    Content type: Research Published on:

  42. High risk, unfavorable classical Hodgkin lymphoma (cHL) includes those patients with primary refractory or early relapse, and progressive disease. To improve the availability of biomarkers for this group of pa...

    Authors: Rajendra Gharbaran, Andre Goy, Takemi Tanaka, Jongwhan Park, Chris Kim, Nafis Hasan, Swathi Vemulapalli, Sreeja Sarojini, Madalina Tuluc, Kip Nalley, Pritish Bhattacharyya, Andrew Pecora and K Stephen Suh
    Citation: Journal of Hematology & Oncology 2013 6:62
    Content type: Research Published on:

  44. Neoadjuvant chemotherapy followed by cytoreduction surgery has been used where an accurate cytologic or pathologic diagnosis is usually required before the initiation of neoadjuvant chemotherapy. However, it i...

    Authors: Yue Wang, Yiying Wang, Jie Li, Zeng Yuan, Bingbing Yuan, Tingguo Zhang, Janiel M Cragun, Beihua Kong and Wenxin Zheng
    Citation: Journal of Hematology & Oncology 2013 6:60
    Content type: Research Published on:

  45. Small molecule inhibitors targeting dysregulated pathways (RAS/RAF/MEK, PI3K/AKT/mTOR, JAK/STAT) have significantly improved clinical outcomes in cancer patients. Recently Bruton’s tyrosine kinase (BTK), a cru...

    Authors: Akintunde Akinleye, Yamei Chen, Nikhil Mukhi, Yongping Song and Delong Liu
    Citation: Journal of Hematology & Oncology 2013 6:59
    Content type: Review Published on:

  46. Myelodysplastic syndromes (MDS) are hematological malignancies of unclear etiology where oxidative stress may contribute to the pathogenesis. Methylarginines, naturally occurring inhibitors of NO synthase, can...

    Authors: Jana Štikarová, Jiří Suttnar, Kristýna Pimková, Leona Chrastinová-Mášová, Jaroslav Čermák and Jan E Dyr
    Citation: Journal of Hematology & Oncology 2013 6:58
    Content type: Letter to the Editor Published on:

  48. High concentrations of plasmatic IgE have been related to distinct systemic inflammatory conditions that frequently predispose individuals to hypersensitivity reactions. Although effects of IgE have been sugge...

    Authors: Guillermina Yanek Jiménez-Andrade, Alfredo Ibarra-Sánchez, Diana González, Mónica Lamas and Claudia González-Espinosa
    Citation: Journal of Hematology & Oncology 2013 6:56
    Content type: Research Published on:

  49. Lenalidomide is an immunomodulatory agent which has been approved for multiple myeloma. Lenalidomide is also effective in and tolerated well by patients with follicular lymphoma, diffuse large B-cell lymphoma,...

    Authors: Madhav Desai, Kate J Newberry, Jorge Romaguera, Liang Zhang, Zhishuo Ou and Michael Wang
    Citation: Journal of Hematology & Oncology 2013 6:55
    Content type: Review Published on:
JHO logo
Submit manuscript

Follow

Annual Journal Metrics

  • 2022 Citation Impact
    28.5 - 2-year Impact Factor
    23.1 - 5-year Impact Factor
    4.045 - SNIP (Source Normalized Impact per Paper)
    6.046 - SJR (SCImago Journal Rank)

    2023 Speed
    5 days submission to first editorial decision for all manuscripts (Median)
    59 days submission to accept (Median)

    2023 Usage 
    3,173,795 downloads
    2,671 Altmetric mentions

On the blog

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here. 

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us